(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)- 1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist

Journal of Medicinal Chemistry

Volumn 40, Issue 3, 1997, Pages 331-341

  Semple, Graeme ^a   Ryder, Hamish ^a   Rooker, David P ^a   Batt, Andrzej R ^a   Kendrick, David A ^a   Szelke, Michael ^a   Ohta, Mitsuaki ^b   Satoh, Masato ^b   Nishida, Akito ^b   Akuzawa, Shinobu ^b   Miyata, Keiji ^b  

^a Chilworth Research Centre   (United Kingdom)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 2 OXO 1 PIVALOYLMETHYL 5 (2 PYRIDYL) 1H 1,4 BENZODIAZEPIN 3 YL] 3 [3 (METHYLAMINO)PHENYL]UREA; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; GASTRIN ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GASTROESOPHAGEAL REFLUX; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; STOMACH ACID SECRETION;

ADMINISTRATION, ORAL; ANIMALS; BENZODIAZEPINES; BENZODIAZEPINONES; BINDING, COMPETITIVE; BRAIN; DEVAZEPIDE; DOGS; GASTRIC ACID; HORMONE ANTAGONISTS; MOLECULAR STRUCTURE; PANCREAS; PENTAGASTRIN; PHENYLUREA COMPOUNDS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; SINCALIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 14444288026     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960669+     Document Type: Article

References (35)

1. Larsson, H.; Carlsson, E.; Junggren, U.; Olbe, L.; Sjostrand, S. E.; Skanberg, I.; Sundell, G. Inhibition of Gastric Acid Secretion by Omeprazole in the Dog and Rat. Gastroenterology 1983, 85, 900-907.
2. Lind, T.; Cederberg, C.; Ekenved, G.; Haglund, U.; Olbe, L. Effect of Omeprazole - A Gastric Proton Pump Inhibitor - on Pentagastrin Stimulated Acid Secretion in Man. Gut 1983, 24, 270-276.
3. +-ATPase Activity. J. Biol. Chem. 1985, 260, 13681-13684.
4. Betton, G. R.; Dormer, C. S.; Wells, T.; Pert, P.; Price, C. A.; Buckley, P. Gastric ECL-cell Hyperplasia and Carcinoids in Rodents Following Chronic Administration of H2-antagonists SK&F 93479 and Oxmetidine and Omeprazole. Toxicol. Pathol. 1988, 16, 288-298.
5. Carney, J. A.; Go, V. L.; Fairbanks, V. F.; Moore, S. B.; Alpont, E. C.; Nora, F. E. The Syndrome of Gastric Argyrophil Carcinoid Tumors and Nonantral Gastric Atrophy. Ann. Intern. Med. 1983, 99, 761-766.
6. Ekman, L.; Hansson, E.; Havu, N.; Carlsson, E.; Lundberg, C. Toxicological Studies on Omeprazole. Scand. J. Gastroenterol. 1985, 20, Suppl. 108, 53-69.
7. (a) Brunner, G.; Lamberts, R.; Creutzfeldt, W. Efficacy and Safety of Omeprazole in the Long-term Treatment of Peptic Ulcer and Reflux Oesophagitis Resistant to Ranitidine. Digestion 1990, 47, Suppl. 1, 64-68.
8. (b) Berlin, R. G. Omeprazole: Gastrin and Gastric Endocrine Cell Data from Clinical Studies. Dig. Dis. Sci. 1991, 36, 129-136.
9. Lee, Y. M.; Beinborn, M.; McBride, E. W.; Lu, M.; Kolakowski, L. F.; Kopin, A. S. The Human Brain Cholecystokinin-B/Gastrin Receptor. J. Biol. Chem. 1993, 268, 8164-8169.
10. Singh, P.; Owlia, A.; Espeijo, R.; Dai, B. Novel Gastrin Receptors Mediate Mitogenic Effects of Gastrin and Processing Intermediates on Swiss 3T3 Fibroblasts. Absence of Detectable Cholecystokinin (CCK)-A and CCK-B Receptors. J. Biol. Chem. 1995, 270, 8429-8438.
11. Nishida, A.; Miyata, K.; Tsutsumi, R.; Yuki, H.; Akuzawa S.; Kobayashi. A.; Kamato, T.; Ito, H.; Yamano, M.; Katuyama, Y.; Ohta, M.; Honda, K. Pharmacological Profile of (R)-1-[2,3-Dihydro-1-(2′-methylphenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a New Potent and Selective Gastrin/Cholecystokinin-B Receptor Antagonist in Vitro and in Vivo. J. Pharmacol. Exp. Ther. 1994, 269, 725-731.
12. Satoh, M.; Kondoh, Y.; Okamoto, Y.; Nishida, A.; Miyata, K.; Ohta, M.; Mase T.; Murase, K. New 1,4-Benzodiazepin-2-one Derivatives as Gastrin/Cholecystokinin-B Antagonists. Chem. Pharm. Bull. 1995, 43, 2159-2167.
13. Semple, G.; Ryder, H.; Kendrick, D. A.; Szelke, M.; Ohta, M.; Satoh, M.; Nishida, A.; Akuzawa S.; Miyata, K. Synthesis and Biological Activity of 1-Alkylcarbonylmethyl Analogues of YM022. Bioorg. Med. Chem. Lett. 1996, 6, 51-54.
14. Semple, G.; Ryder, H.; Kendrick, D. A.; Szelke, M.; Ohta, M.; Satoh, M.; Nishida, A.; Akuzawa S.; Miyata, K. Synthesis and Biological Activity of 5-Heteroaryl Benzodiazepines: Analogues of YM022. Bioorg. Med. Chem. Lett. 1996, 6, 55-59.
15. Bock, M. G., DiPardo, R. M., Evans, B. E., Rittle, K. E., Veber,.D. F., Freidinger, R. M., Hirschfield, J.; Springer, J. P. Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones. J. Org. Chem. 1987, 52, 3232-3239.
16. Zoller, U.; Ben-Ishai, D. Amidoalkylation of Mercaptans with Glyoxylic Acid Derivatives. Tetrahedron 1975, 31, 863-866.
17. Bock, M. G., DiPardo, R. M., Evans, B. E., Rittle, K. E., Veber, D. F.; Freidinger, R. M. An Expedient Synthesis of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one. Tetrahedron Lett. 1987, 28, 939-942.
18. Semple, G.; Ryder, H.; Ohta, M.; Satoh, M. A Facile Large Scale Synthesis of Optically Active 3-Amino-5-(2-pyridyl)-1,4-benzodiazepin-2-one Derivatives. Synth. Commun. 1996, 26, 721-727.
19. Sherrill, R. G.; Sugg, E. E. An Improved Synthesis and Resolution of 3-Amino-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-ones. J. Org. Chem. 1995, 60, 730-734.
20. Katritzky, A. R.; Urogdi, L.; Mayence, A. Benzotriazole Assisted Synthesis of Monoacyl Aminals and Their Peptide Derivatives. J. Org. Chem. 1990, 55, 2206-2214.
21. Bock, M. G.; DiPardo, R. M.; Evans, B. E.; Rittle, K. E.; Whitter, W. L.; Garsky, V. M.; Gilbert, K. F.; Leighton, J. L.; Carson, K. L.; Mellin, E. C.; Veber, D. F.; Chang, R. S. L.; Lotti, V. J.; Freedman, S. B.; Smith, A. J.; Patel, S.; Anderson, P. S.; Freidinger, R. M. Development of 1,4-Benzodiazepine Cholecystokinin Type B Antagonists. J. Med. Chem. 1993, 36, 4276-4292.
22. Reider, P. J.; Davis, P.; Hughes, D. L.; Grabowski, E. J. J. Crystallisation-Induced Assymetric Transformation: Stereospecific Synthesis of a Potent Peripheral CCK Antagonist, J. Org. Chem. 1987, 52, 955-957.
23. Chang, R. S. L.; Lotti V. J. Biochemical and Pharmacological Characterization of an Extremely Potent and Selective Nonpeptide Choleeystokinin Antagonist. Proc. Natl. Acad. Sci, U.S.A. 1986, 83, 4923-4926.
24. Lin, J. H., Storey, D. E.; Chen, I.-W.; Xu, X. Improved Oral Absorption of L-365,260, A Poorly Soluble Drug. Biopharm. Drug Disposit. 1996, 17, 1-15.
25. Chambers, M. S.; Hobbs, S. C.; Fletcher, S. R.; Matassa, V. G.; Mitchell, P. J.; Watt, A. P.; Baker, R.; Freedman, S. B.; Patel, S.; Smith, A. J. L-708,474: The C5-Cyclohexyl Analogue of L-365,260, a Selective High Affinity Ligand for the CCK-B/ Gastrin Receptor. Bioorg. Med. Chem. Lett. 1993, 3, 1919-1924.
26. (a) Showell, G. A.; Bourrain, S.; Neduvelil, J. G.; Fletcher, S. R.; Baker, R.; Watt, A. P.; Fletcher, A. E.; Freedman, S. B.; Kemp, J. A.; Marshall, G. R.; Patel, S.; Smith, A. J.; Matassa, V. G. High Affinity and Potent, Water-Soluble 5-Amino-1,4-benzodiazepine CCK-B/Gastrin Receptor Antagonists Containing a Cationic Solublizing Group. J. Med. Chem. 1994, 37. 719-721.
27. (b) Showell, G. A.; Bourrain, S.; Fletcher, S. R.; Neduvelil, J. G.; Fletcher, A. E.; Freedman, S. B.; Patel, S.; Smith, A. J.; Marshall, G. R.; Graham, M. I.; Sohal, B.; Matassa, V. G. C5-Piperazinyl-1,4-benzodiazepines. Water Soluble, Orally Bioavailable CCK-B/Gastrin Receptor Antagonists. Bioorg. Med. Chem. Lett. 1995, 5, 3023-3026.
28. Bock, M. G.; DiPardo, R. M.; Mellin, E. C.; Newton, R. C.; Veber, D. F., Freedman, S. B.; Smith, A. J.; Patel, S.; Kemp, J. A.; Marshall, G. R.; Fletcher, A. E.; Chapman, K. L.; Anderson, P. S.; Freidinger, R. M. Second-Generation Benzodiazepine CCK-B Antagonists. Development of Sub-nanomolar Analogues with Selectivity and Water Solubility. J. Med. Chem. 1994, 37, 722-724.
29. Chambers, M. S.; Hobbs, S. C.; Graham, M. I.; Watt, A. P.; Fletcher, S. R.; Baker, R.; Freedman, S. B.; Patel, S.; Smith, A. J. Matassa, V. G. Potent, Selective Water-Soluble Bezodiazepine-Based CCK-B Receptor Antagonists that Contain Lipophilic Carboxylate Surrogates. Bioorg. Med. Chem. Lett. 1995, 5, 2303-2308.
30. Lowe, J. A.; Drozda, S. E.; McLean, S.; Bryce, D. K.; Crawford, R. T.; Zorn, S.; Morrone, J.; Appleton, T. A.; Lombardo, F. A Water Soluble Benzazepine Cholecystokinin-B Receptor Antagonist. Bioorg. Med. Chem. Lett. 1995, 5, 1933-1936.
31. Satoh, M.; Okamoto, Y.; Koshio, H.; Ohta, M.; Nishida, A.; Akuzawa, S.; Miyata, K.; Mase T.; Semple, G. Biological Activity of Analogues of YM022. Novel (3-Amino Substituted Phenyl)-urea Derivatives of 1,4-Benzodiazepin-2-one as Gastrin/Cholecystokinin-B Receptor Antagonists. Chem. Pharm. Bull. 1996, 44, 1412-1414.
32. Takinami, Y.; Yuki, H.; Nishida, A.; Akuzawa, S.; Uchida, A.; Takemoto, Y.; Ohta, M.; Satoh, M.; Semple, G.; Miyata, K. (R)-1-[2,3-Dihydro-2-oxo-1-pivaloylmethyl-5-(2′-pyridyl)-1H-1,4- benzodiazepin-3-yl]-3-(3-methylaminophenyl) Urea (YF476) is a New Potent and Selective Gastrin/Cholecystokinin (CCK)-B Receptor Antagonist In Vitro and In Vivo. Aliment. Pharmacol. Ther., 1996, in press.
33. Fryer, R. I.; Schmidt, R. A.; Sternbach, L. H. Quinazolines and 1,4-Benzodiazepines XVII. Synthesis of 1,3-Dihydro-5-pyridyl-2H-1,4-benzodiazepine Derivatives. J. Pharm. Sci. 1964, 53, 264-268.
34. van der Werth, A.; Lederer, F. German Patent No. 2,256,614, 1973.
35. Heidenhain, R. Pflugers Arch. 1879, 19, 148.